<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075803</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0101</org_study_id>
    <secondary_id>BMT CTN 0101</secondary_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00075803</nct_id>
    <nct_alias>NCT00322088</nct_alias>
  </id_info>
  <brief_title>Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)</brief_title>
  <official_title>A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a Phase III, randomized, double-blind, multicenter, prospective,
      comparative study of fluconazole versus voriconazole for the prevention of fungal infections
      in allogeneic transplant recipients. Recipients will be stratified by center and donor type
      (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm
      in a 1:1 ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Allogeneic blood and marrow transplant patients are highly susceptible to invasive fungal
      infection prior to engraftment, due to neutropenia and mucosal injury. After engraftment, an
      impairment of cell mediated immunity from graft-versus-host disease (GVHD) and the use of
      aggressive immunosuppressive therapies, such as corticosteroids, leave patients vulnerable to
      invasive fungal infections. Recipients of alternate donor transplants are especially
      susceptible due to slow reconstitution of cell mediated immunity.

      Fluconazole prophylaxis in prospective randomized trials of both autologous and allogeneic
      transplant recipients has been demonstrated to reduce invasive fungal infections due to
      yeasts prior to engraftment. A prolonged course of fluconazole given during the first 75 days
      (to cover the early post-engraftment period of risk) is highly effective in the prevention of
      early and later yeast infections. This has translated into a survival benefit. A recent
      analysis of long-term outcomes of these individuals demonstrated a continuing benefit beyond
      the course of prophylaxis with a further benefit in survival. In another study of various
      factors associated with survival after matched unrelated donor transplants, fluconazole
      prophylaxis was an independent predictor for overall survival in a multivariate analysis.
      Fluconazole prophylaxis has been found to be effective and safe with few substantive drug
      interactions and has been widely adopted by transplant clinicians.

      DESIGN NARRATIVE:

      This is a randomized, double-blind, multicenter, prospective, comparative study of
      fluconazole versus voriconazole for the prevention of fungal infections in allogeneic
      hematopoietic transplant recipients and cord blood recipients in children under the age of
      12. Prior to the start of the pre-transplant conditioning regimen, participants will give
      written informed consent and be screened for eligibility. Participants who meet all entry
      criteria will be assigned randomly to voriconazole or fluconazole within 72 hours of Day 0.
      Participants will begin the study drug on Day 0 (after completion of the conditioning
      regimen). Day 0 is defined as the day infusion of the stem cell product is completed. The
      study drug will be continued until Day 100 following transplant or until one or more criteria
      for early withdrawal are met. Continuation of the study drug beyond Day 100 is permitted for
      participants who meet specific criteria. The development of any fungal infection during
      prophylaxis will be classified according to the definitions listed in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Invasive Fungal Infections (IFI)</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of proven, probably, or presumptive IFI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days</measure>
    <time_frame>100, 180, and 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>100, 180, and 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>100, 180, and 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Use of Amphotericin B or Caspofungin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Use of Amphotericin B or Caspofungin</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)</measure>
    <time_frame>100 and 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil Engraftment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Platelet Engraftment</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to Engraft</measure>
    <time_frame>day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Lymphoma</condition>
  <condition>Infection</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of fluconazole is 400 mg by mouth or intravenous drip.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients &gt; 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients &lt; 12 years, intravenous doses will be prepared.</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients &gt; 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients &gt; 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age &lt; 12 years.</description>
    <arm_group_label>Voriconazole</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must receive an allogeneic peripheral blood or marrow transplant from a family or
             unrelated donor, or for children under the age of 12, a cord blood transplant from
             either a sibling or other donor

          -  Must have a 5 or 6 of 6 human leukocyte antigens (HLA)-matched donor. The match may be
             determined at serologic level for HLA-A and HLA-B loci. For sibling donors, matching
             may be determined at serologic level for HLA-DR; for unrelated donors, matching for
             HLA-DRB1 must be at the high-resolution molecular level

          -  Must have one of the following underlying diseases:

               1. Acute myelogenous leukemia (AML)

               2. Acute lymphocytic leukemia (ALL)

               3. Acute undifferentiated leukemia (AUL)

               4. Acute biphenotypic leukemia in first or second complete remission

               5. Chronic myelogenous leukemia (CML) in either chronic or accelerated phase

               6. One of the following myelodysplastic syndrome(s) (MDS):

                    1. Refractory anemia

                    2. Refractory anemia with ringed sideroblasts

                    3. Refractory cytopenia with multilineage dysplasia

                    4. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts

                    5. Refractory anemia with excess blasts-1 (5-10% blasts)

                    6. Refractory anemia with excess blasts-2 (10-20% blasts)

                    7. MDS, unclassified

                    8. MDS associated with isolated del (5q)

                    9. Chronic myelomonocytic leukemia (CMML)

               7. Lymphoma (including Hodgkin's) with chemosensitive disease (at least 50% response
                  to chemotherapy) and receiving a related donor transplant

          -  Receiving myeloablative conditioning regimens

          -  Adequate physical function (cardiac, hepatic, renal, and pulmonary), within 6 weeks of
             initiation of conditioning (preferably within 4 weeks) unless otherwise specified

          -  Baseline galactomannan blood samples drawn within 30 days prior to randomization with
             the results available prior to randomization (72 hours prior to transplant)

          -  Chest computed tomography (CT) scans within 6 weeks prior to randomization if the
             results of the baseline galactomannan blood sample are not available prior to
             randomization (72 hours prior to transplant)

        Exclusion Criteria:

          -  Invasive yeast infection within the 8 weeks prior to conditioning regimen initiation.
             Patients are eligible if colonized or have had superficial infection. Patients with a
             history of candidemia greater than 8 weeks prior to conditioning must have a negative
             blood culture within 14 days of conditioning (within 7 days is recommended), no
             clinical signs of candidemia, and may not still require antifungal therapy

          -  Presumptive, proven, or probable aspergillus or other mold infection or deep mycoses
             (including hepatosplenic candidiasis) within 4 months prior to conditioning regimen
             initiation

          -  Uncontrolled viral or bacterial infection at the time of study registration

          -  Pregnant or breastfeeding. Women of child-bearing age must avoid becoming pregnant
             while receiving antifungal agents

          -  Karnofsky performance status less than 70% or Lansky status less than 50% for patients
             under 16 years old unless approved by the medical monitor or protocol chair

          -  History of allergy or intolerance to azoles (e.g., fluconazole, itraconazole,
             voriconazole, posaconazole, ketoconazole, miconazole, clotrimazole)

          -  Requiring therapy with rifampin, rifabutin, carbamazepine, cisapride (Propulsid®),
             terfenadine (Seldane®), astemizole (Hismanal®), ergot alkaloids, long-acting
             barbiturates, or who have received more than 3 days treatment with rifampin or
             carbamazepine within 7 days prior to conditioning regimen initiation. Patients on
             therapeutic anticoagulation with coumadin (1 mg/day for port prophylaxis is permitted)

          -  Receiving sirolimus

          -  Prolonged QTc syndrome at study entry

          -  HIV positive

          -  Receiving another investigational drug unless cleared by the medical monitors

          -  Received a prior allogeneic or autologous transplant

          -  Active central nervous system disease

          -  On fungal prophylaxis during conditioning regimen (it is recommended that fungal
             prophylaxis be suspended once patient is enrolled)

          -  Prior cancer, other than resected basal cell carcinoma or treated carcinoma in-situ.
             Cancer treated with curative intent less than 5 years previously will not be allowed
             unless approved by the medical monitor or protocol chair. Cancer previously treated
             with curative intent over 5 years ago will be allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins/SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Brigham &amp; Womens</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute/BMT</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah BMT/Univ of Utah Med School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network (BMT CTN)</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 9;116(24):5111-8. doi: 10.1182/blood-2010-02-268151. Epub 2010 Sep 8.</citation>
    <PMID>20826719</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JM, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep 1;70(17):1518-27. doi: 10.2146/ajhp120599.</citation>
    <PMID>23943184</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2004</study_first_posted>
  <results_first_submitted>February 22, 2013</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic and Myeloproliferative Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from November 2003 through September 2006</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluconazole</title>
          <description>fluconazole prophylaxis</description>
        </group>
        <group group_id="P2">
          <title>Voriconazole</title>
          <description>voriconazole prophylaxis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluconazole</title>
          <description>fluconazole prophylaxis</description>
        </group>
        <group group_id="B2">
          <title>Voriconazole</title>
          <description>voriconazole prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="305"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="9" upper_limit="65"/>
                    <measurement group_id="B2" value="43" lower_limit="3" upper_limit="66"/>
                    <measurement group_id="B3" value="43" lower_limit="3" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Graft Source</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute myeloid leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute lymphoblastic leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic myelogenous leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Leukocyte Antigen (HLA) Match</title>
          <description>Patients must have a 5 or 6 of 6 HLA-matched donor. The match may be determined at serologic level for HLA-A and HLA-B loci.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 of 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 of 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky/Lansky Performance Status</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>90% - 100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant</title>
        <time_frame>180 days</time_frame>
        <population>All randomized patients were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant</title>
          <population>All randomized patients were included in the analysis</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="69.6" upper_limit="79.5"/>
                    <measurement group_id="O2" value="78.2" lower_limit="73.1" upper_limit="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Invasive Fungal Infections (IFI)</title>
        <description>Incidence of proven, probably, or presumptive IFI</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Invasive Fungal Infections (IFI)</title>
          <description>Incidence of proven, probably, or presumptive IFI</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="9.8" upper_limit="17.6"/>
                    <measurement group_id="O2" value="12.7" lower_limit="9.0" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days</title>
        <time_frame>100, 180, and 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.2" upper_limit="12.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="3.1" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="7.7" upper_limit="14.7"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.4" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="9.8" upper_limit="17.6"/>
                    <measurement group_id="O2" value="12.7" lower_limit="9.0" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>100, 180, and 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="80.9" upper_limit="89.0"/>
                    <measurement group_id="O2" value="90.1" lower_limit="86.2" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="75.0" upper_limit="84.1"/>
                    <measurement group_id="O2" value="81.2" lower_limit="76.3" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="64.6" upper_limit="75.1"/>
                    <measurement group_id="O2" value="67.8" lower_limit="62.1" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Free Survival</title>
        <time_frame>100, 180, and 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Free Survival</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="78.3" upper_limit="86.9"/>
                    <measurement group_id="O2" value="86.1" lower_limit="81.7" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="69.6" upper_limit="79.5"/>
                    <measurement group_id="O2" value="73.9" lower_limit="68.5" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="57.4" upper_limit="68.6"/>
                    <measurement group_id="O2" value="61.2" lower_limit="55.5" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Use of Amphotericin B or Caspofungin</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Use of Amphotericin B or Caspofungin</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="24.9" upper_limit="35.5"/>
                    <measurement group_id="O2" value="24.1" lower_limit="19.2" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Use of Amphotericin B or Caspofungin</title>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Use of Amphotericin B or Caspofungin</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of days on study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="27" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="34" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start day of empiric antifungal therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="33"/>
                    <measurement group_id="O2" value="12" lower_limit="8" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of empiric antifungal therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)</title>
        <time_frame>100 and 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GVHD grade II-IV at day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute GVHD grade III-IV at day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GVHD at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy</title>
        <description>Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy</title>
          <description>Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GM+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neutrophil Engraftment</title>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Platelet Engraftment</title>
        <time_frame>180 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure to Engraft</title>
        <time_frame>day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Failure to Engraft</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>voriconazole prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFI after relapse/progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI before engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI who had failure to engraft</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI after aGVHD (grades II-IV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI while on study drug (up to day 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI after premature withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI after start other prophylaxis (not study drug)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFI after empiric therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluconazole</title>
          <description>fluconazole prophylaxis</description>
        </group>
        <group group_id="E2">
          <title>Voriconazole</title>
          <description>voriconazole prophylaxis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>HUS/TTP/thrombotic microangiopathy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>AV Block - third Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>EKG Abnormality</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>troponin level grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photopsia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/Stomatitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death at home, unexpected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Allergic Reaction / Hypersensitivity</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatic Dysfunction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Magnesium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pain, Site Right Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PTLD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Guillian-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sagittal Sinus Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Mental Status Change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary Frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmoary embolus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vascular Leak Syndrome</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>EKG Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction / Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Liver Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy DiFronzo, PhD</name_or_title>
      <organization>NHLBI</organization>
      <phone>301-435-0065</phone>
      <email>difronozon@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

